The Senate Judiciary Committee reignited the policy battle over soaring prescription drug costs on November 17, 2026, advancing a slate of bipartisan bills designed to crack open the opaque practices of the pharmaceutical supply chain and lower prices for millions of Americans. With Chairman Senator Chuck Grassley (R-Iowa) presiding, lawmakers and witnesses spotlighted the influence of Pharmacy Benefit Managers (PBMs) and called for greater transparency to address what many describe as systemic price inflation on vital medicines.

Six reform bills aimed at increasing competition and transparency were sent forward by the committee. One of these measures, the Affordable Prescriptions for Patients Act, achieved unanimous Senate passage in July 2026, but the remaining five have yet to reach a floor vote. The legislative package seeks to tackle entrenched tactics—such as so-called ‘product hopping,’ patent gaming, and pay-for-delay arrangements—that critics argue block cheaper drugs from reaching patients. Enhanced transparency requirements for PBMs—powerful intermediaries that negotiate drug prices and rebates—are at the heart of the effort, as patients, employers, and pharmacies struggle with unpredictable costs and limited clarity on pricing mechanisms.

Testifying before the committee, Iowa Pharmacy Association CEO Matthew Pitlick stressed that Americans, particularly those in rural areas, desperately need greater competition and openness to lower their pharmaceutical bills. Merith Basey, who leads Patients For Affordable Drugs Now, noted that nearly one in three Americans struggles to pay for prescribed medications and called on the Senate to close longstanding regulatory and patent loopholes that keep prices high.

Bringing a disruptive industry perspective, Dr. Alex Oshmyansky of the Mark Cuban Cost Plus Drug Company detailed a simpler pricing model—transparent costs marked up by a fixed percentage and fees—which he argued could save Medicare billions annually compared to current PBM-negotiated plans. He pointed out that, under the prevailing system, excessive markups often leave patients paying as much as 100 times more for the same drug than through direct-purchase models. Neeraj Sood of USC’s Schaeffer Institute recommended enforcing fiduciary duties on PBMs, obligating them to prioritize patient and payer interests—a move he argued would align incentives and reduce costs.

Bipartisan urgency was echoed by Senator Dick Durbin (D-IL), who called for swift adoption of the Drug-price Transparency for Consumers Act, requiring prescription drug advertisements to include price disclosures. The legislation, backed by both Durbin and Grassley, targets the billions spent annually on direct-to-consumer ads that critics say drive up demand and insulate manufacturers from competitive forces.

While the legislative push has gained momentum, significant obstacles remain. Key stakeholders and committee members highlighted the ongoing wait for the Federal Trade Commission’s comprehensive study on PBMs, begun in 2022, which is expected to inform further policy actions but remains incomplete. As a result, advocates warn that crucial decisions about the wider prescription drug market are occurring without the benefit of the FTC’s final, evidence-based recommendations.

The current flurry of bipartisan engagement builds on years of Senate scrutiny, including prior hearings on PBM practices and the struggle of rural pharmacies, led in part by Grassley. With Americans continuing to pay among the world’s highest medication prices, the committee’s actions signal intensified congressional resolve, even as reform bills await decisive votes and federal regulators prepare their findings. As the debate enters its next phase, both lawmakers and consumer advocates insist that transparency and competition remain essential for delivering affordable drugs to American families.